After her father died from a preventable prescribing error, pharma professional Jill Donohue dedicated her career to improving how the industry communicates. This personal tragedy became the driving force behind her work on ethical persuasion and patient-centric behavior change.

Dealing with regulatory bodies can be terrifying, especially for a startup facing a recall. The key is to present objective facts, demonstrate a rigorous process, and make decisions that protect the product and patient. This builds trust and ensures long-term viability.

When a billion-dollar drug trial fails, society learns nothing from the operational process. The detailed documentation of regulatory interactions, manufacturing, and trial design—the "lab notes" of clinical development—is locked away as a trade secret and effectively destroyed, preventing collective industry learning.

Voyager CEO Al Sandrock supports the FDA's use of accelerated approval for severe diseases but argues it must be coupled with industry accountability. He praises Amelix for voluntarily pulling its ALS drug after a failed confirmatory trial, framing such responsible actions as essential for maintaining the FDA's willingness to be flexible with approvals based on surrogate endpoints.

The public's deep mistrust of the pharmaceutical industry isn't baseless; it's rooted in the 1990s cultural shift toward a shareholder-first, 'greed is good' philosophy. This era led to questionable practices that created lasting cracks in public trust that the industry must still actively work to repair.

Bio is creating a formal system for biotech companies to report challenges with the FDA. Bio will synthesize this feedback monthly and present it directly to FDA leadership, creating a novel channel to elevate systemic issues and improve accountability.

A key employee at Jared Bauer's first company taught him that agencies like the FDA are not enemies. By understanding their goal is to protect patients, he learned to partner with them and proactively address their concerns, a mindset he found highly effective.

This landmark case provides a viable, though difficult, path for institutional payers like union funds and health plans to recover economic losses from fraudulent drug marketing. It shifts the dynamic from simply absorbing these costs to actively using their own data to prove that misinformation altered prescribing patterns.

The Ninth Circuit ruled that physicians' independent judgment doesn't break the causal chain in drug fraud cases. Instead, they are considered 'foreseeable intermediaries,' allowing third-party payers to sue manufacturers directly for economic harm caused by misleading information that influenced prescribing decisions.